More Than 20 Provinces, Landing Second Batches Of National Drugs, Chronic Diseases, Commonly Used Drugs Sharply Reduced Prices

The second batch of collecting results is coming down one after another. As of May 8th, according to incomplete statistics of twenty-first Century economic report reporters, including Shandong, Guangdong, Jiangxi, Liaoning, Jiangsu and other more than 20 provinces, one after another, the results of the election were landing, and the related chronic diseases were entering the hospital.

In January 20th, the second batch of state organs centralized procurement of pharmaceuticals produced the results of mid - selection. 32 varieties purchased successfully, and the price of drugs dropped significantly. The national health insurance agency said that all patients in the country should be able to use the selected drugs in April 2020.

The price of chronic disease drugs will greatly reduce the burden of patients. For example, Wu Weipei, director of the Department of pharmacy of Jiangmen Central Hospital in Guangdong province has counted out such an account: "take the patients with chronic hypertension as an example, they need to take 3 kinds of medicine, Amlodipine Besylate Tablets, Atorvastatin Calcium Tablets and Clopidogrel Bisulfate Tablets every day, and save 22.8 yuan per day after reducing the price, saving 638 yuan a month."

Chronic diseases often reduce prices obviously.

In order to further reduce the drug price of virtual high and effectively reduce the burden of drug expenses, the results of the second batch of state organizations' centralized procurement and use of drugs were officially announced in January 17, 2020, and a total of 32 varieties were selected.

According to the plan of National Health Insurance Bureau, drug price reduction began in April.

It is understood that since April 1st, the local health insurance bureau has been trading in accordance with the selected price of the two batch of drugs purchased by state organizations.

For example, the Hebei Provincial Health Insurance Bureau requires that the production and distribution enterprises should do well in the supply of medicines. Before March 25th, drug manufacturers should have sufficient stock of medicines selected according to medical institutions, while distribution companies will distribute the selected medicines at all levels to medical institutions at all levels before March 30th. Starting from 0:00 on April 1st, the designated medical institutions at all levels should use the selected drugs and sell them at the median price.

In April 11th, Jiangxi formally implemented the second batch of state organizations for centralized procurement of 32 drugs. The average price of the 32 drugs was 53%, the biggest decrease was 93%, especially for acarbose, glimepiride and other chronic diseases.

Since April 27th, Jiangsu has fully implemented the results and the supporting policies of the second batch of centralized drug procurement by state organizations. It is understood that the largest drug in Jiangsu province is Clindamycin Hydrochloride Capsules, which is produced by Chongqing Pharmaceutical Co., Ltd., and the original price of 0.25g was 4.67 yuan / grain, and the price was 0.14 yuan / grain after the price was cut. Hypoglycemic drugs such as acarbose, glimepiride and other chronic diseases have been widely used. Such as Acarbose Capsules produced by Sichuan green leaf pharmaceutical Limited by Share Ltd, the specifications are packaged 50mg x 30, and the original provincial network price is 41.23 yuan, after the price reduction is 9.6 yuan.

In April 27th, Guangdong province began to implement 32 new second groups of drugs sold by the state organization in the centralized procurement. Since April 28th, Henan has fully implemented the second batch of selected drugs in the state concentration and quantity purchase, and requested all levels of medical institutions to fully implement them before April 30, 2020.

According to the medical insurance bureau of Henan Province, it is estimated that the purchase cost of related drugs will be reduced from 847 million yuan to 180 million yuan in Henan after the second batch of state concentration is purchased. The cost of medicine can be saved by 667 million yuan. In order to further reduce the burden of patients, our province has carried out a gradient price reduction with the general name of the unselected drugs, with an average decrease of 33.76%.

In terms of price reduction, the price of candesartan (8mg * 14 tablets / boxes) was reduced from 55.3 yuan per box to 3.69 yuan, a decrease of 93.33%. The oral antidiabetic drug acarbose (50mg * 30 tablets / box) was reduced from 61.2 yuan per box to 5.42 yuan, a decrease of 91.14%. The antitumor drug, 0.25g (120 * / box), dropped from original 12200 yuan to 2800 yuan. The price is reduced by 9400 yuan per box.

Wu Weipei cited his Jiangmen Central Hospital as an example. The dosage of amlodipine, Atorvastatin Calcium Tablets, and Atorvastatin Calcium Tablets in 2019 was about 37 thousand boxes, 21 thousand boxes and 53 thousand boxes. After the price cut, the annual burden of the patients was reduced by about 5 million 440 thousand yuan. The entecavir tablets used by liver disease patients and the targeted drug Gefitinib Tablets used in lung cancer patients can reduce their burden by about 1 million 100 thousand yuan and 4 million 450 thousand yuan a year respectively.

Strengthening management of chronic disease patients

In fact, chronic diseases have become the number one killer of global residents. In 2019, the prevalence rate of chronic diseases has reached 23%, and the number of deaths has accounted for 86% of the total deaths. It is predicted that the incidence of cancer, diabetes and hypertension will increase to 0.7%, 14.4% and 27.8% respectively by 2026. The rising incidence of chronic diseases will lead to long-term administration of drugs and management costs of chronic diseases, leading to an increase in management expenses for chronic diseases in China. It is estimated that China's chronic disease expenditure will rise to around 5 trillion and 500 billion yuan by 2020.

? ? ? According to statistics from domestic sample hospitals, in 2018, the number of antineoplastic drugs ranked third, with sales volume of 26 billion 500 million yuan, accounting for 11.6%. Cardiovascular drugs ranked fourth, sales amounted to 22 billion 600 million yuan, accounting for 10%, endocrine and metabolic regulation drugs (diabetes) ranked seventh, sales amounted to 13 billion 400 million yuan, 5.9%, and respiratory drugs ranked tenth, with sales of 8 billion 100 million yuan, accounting for 8 billion 100 million. The total sales volume of the four drugs was 70 billion 600 million yuan, accounting for 31.2% of the total market.

Since 2004, China's CDC has carried out monitoring work on chronic diseases and its risk factors for permanent residents in China. In recent years, the state has also strengthened the prevention and treatment of chronic diseases.

In 2016, the state promulgated the "national long term comprehensive prevention and control demonstration zone construction management measures", through the establishment of national level chronic disease comprehensive prevention and control demonstration area, to improve the level of chronic disease management in China. In 2017, the general office of the State Council also issued "China's long-term plan for chronic diseases (2017-2025 years)" (hereinafter referred to as "planning"), deploying the prevention and control of chronic diseases in the future, and comprehensively controlling the risk factors of chronic diseases.

According to the plan, by 2025, the risk factors of chronic diseases can be effectively controlled, and the whole population life cycle health management can be achieved. The premature mortality rate of 30-70 year olds due to cardiovascular, cerebrovascular diseases, cancer, chronic respiratory diseases and diabetes is 20% lower than that in 2015. We should gradually improve the health expectancy of residents and effectively control the burden of chronic diseases.

However, the Prospective Research Institute pointed out in the report that more than 60% of chronic disease patients did not take medicine according to the doctor's advice, and lack of scientific and rational management methods for chronic diseases, which resulted in poor efficacy of drugs, relapse of patients and complications.

The director of Department of Hematology, a cancer hospital, told the twenty-first Century business reporter that one of the main reasons for the poor compliance of chronic disease patients is the heavy burden of drugs. State purchasing with quantity can help patients reduce the burden of medication.

Chen Qiulin, director of the Social Security Research Office of the Institute of population and labor economics of the Chinese Academy of Social Sciences, said that centralized procurement based on the consistency of quality and curative effect is a good mechanism for enterprises to return to cost and quality competition and benefit patients, doctors, enterprises, medical insurance funds and other parties.

The winning bid has further reduced the cost of patients' expenses while improving the level of clinical medication, and has also received positive feedback from clinical experts. Diabetes experts have pointed out that the safety and effectiveness of the original drug have been fully verified by many clinical trials. After the purchase policy has been landed, the quality of the original research drugs will be substantially reduced, which will reduce the economic burden of patients and provide a strong guarantee for the standardized management of diseases.

?